NW Bio Announces Completion of $12 Million Financing

Majority of Financing from New Investors PR Newswire BETHESDA, Md., Dec. 4, 2017 BETHESDA, Md., Dec. 4, 2017, NWBO, /PRNewswire/ Northwest Biotherapeutics (OTCQB: NWBO) (NWBio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has completed a $12 million financing to fund operations.  The majority of the financing is being provided by new investors. The financing is in the form of Series A Convertible Preferred Stock and Warrants.  The Preferred Stock will be convertible into common stock,
http://bit.ly/2BBf1zl